Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone Acetate

20251 citationsJournal Articlegold Open Access

Authors

Gordon Brown · ipIQ

Sabree Burbage · Johnson & Johnson (United States)

Ibrahim Khilfeh · Johnson & Johnson (United States)

Carmine Rossi · Group for Research in Decision Analysis

Shawn Du · Johnson & Johnson (United States)

Frédéric Kinkead · Group for Research in Decision Analysis

Lilián Díaz

Abstract

Black patients treated with apalutamide experienced significantly higher PSA90 response rates than those treated with abiraterone acetate, suggesting possible clinical benefits from early treatment response in this population.

Topics & Keywords

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Radiopharmaceutical Chemistry and Applications

Publication Details

Published in: Journal of health economics and outcomes research

Volume 12, Issue 2, pp. 270-278

DOI: 10.36469/001c.151273

Field-Weighted Citation Impact: 1.65

Command Palette

Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone Acetate

Authors

Abstract

Topics & Keywords

Publication Details